Drug-makers didn’t raise list prices for as many drugs in January compared to last year and they initiated fewer hikes of 10% or more, according to analysis by Raymond James & Associates. Although 5.5% of price increases reached the 10% level in January this year, 15% did last year and 20% did 2 years ago. […]
johnsonandjohnson
How virtual and mixed reality are changing drug delivery and device design
Kai Worrell believes that virtual and mixed reality may change the way companies design medical devices, and he’s putting that idea into practice. “We think it’s going to transform the way we do feasibility testing and cognitive walk-through simulations,” he said. “We think it’s going to help us understand the cognition of our users, clinical […]
How Sanofi blew its chance with Actelion
Days before entering into exclusive takeover negotiations with Johnson & Johnson (NYSE:JNJ), Actelion (VTX:ATLN) was reportedly fielding an offer from Sanofi (NYSE:SNY). But the Swiss biotech eventually agreed to go with J&J’s $30 billion bid in an all-cash deal at the end of January. Actelion accepted the U.S. healthcare giant’s offer because it provided more certainty, Reuters reported today. The prospectus […]
Trump presses pharma execs on pricing, U.S. production
Executives from pharmaceutical companies including Johnson & Johnson (NYSE:JNJ), Amgen (NSDQ:AMGN), Merck (NYSE:MRK) and Eli Lilly (NYSE:LLY) met with President Donald Trump today to discuss issues ranging from drug pricing to regulatory approval for pharmaceuticals. The president called on the company execs to increase U.S. production and lower “astronomical” drug prices. Although Trump doubled down on his […]
Merck becomes latest to offer insight into drug pricing practices
Last week, Merck (NYSE:MRK) released figures about its U.S. pricing practices, joining a growing list of companies that are revealing their pricing strategies amid criticism of the industry’s price hikes. The company didn’t release price increases of specific products, citing competition concerns. Merck said it would update the list annually at the beginning of each calendar year. […]
Johnson & Johnson’s earnings disappoint, but pharma rev climbs
Shares in Johnson & Johnson (NYSE:JNJ) fell this week after the company missed the consensus top-line forecasts but pulled off earnings beats for both the 4th quarter and 2016. Pharmaceutical sales grew 6.5% for the full-year to $33.5 billion, with an operational increase of 7.4%. Domestic sales climbed nearly 10% and international sales increased 1.8%. New Brunswick, […]
Johnson & Johnson to pay $30B for Actelion
After weeks of exclusive negotiations, Johnson & Johnson (NYSE:JNJ) said on Thursday that it plans to buy Swiss biotech firm Actelion (VTX:ATLN) for $30 billion in an all-cash deal. The companies have reportedly been in talks for months – Sanofi (NYSE:SNY) was also involved in discussions for Actelion, but was sidelined after J&J entered into exclusive negotiations with Actelion last […]
J&J, Actelion still in talks despite Opsumit failure
Although Actelion (VTX:ATLN)’s Opsumit drug candidate missed its primary endpoint in a phase III trial for patients suffering from a deadly heart-lung condition, analysts reportedly concluded that the result is unlikely to have an impact on merger talks with Johnson & Johnson (NYSE:JNJ). The Swiss drugmaker’s trial involved 226 patients with Eisenmenger Syndrome, which causes untreated congenital heart […]
Orthocell, J&J’s DePuy Synthes ink R&D deal for stem cell treatment
Orthocell (ASX:OCC) said today that it landed a research collaboration deal with Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes for its Ortho-ATI stem cell regenerative therapy. The 2 groups are planning a collaborative study for the 1st quarter in 2017, led by Allan Wang from the University of Western Australia. In previous studies, Ortho-ATI has proven […]
J&J to publish list of average drug price increases
Johnson & Johnson (NYSE:JNJ) is reportedly issuing a report next month that will detail how much it has raised the list prices for its prescription drugs. The report will describe average increases in list prices and the average prices after discounts. The move comes after some pharmaceutical companies, including Allergan (NYSE:AGN) and Novo Nordisk (NYSE:NVO), have pledged […]